Skip to main content
. Author manuscript; available in PMC: 2006 Sep 18.
Published in final edited form as: Pediatr Res. 2005 Mar 17;57(5 Pt 1):732–737. doi: 10.1203/01.PDR.0000159513.51898.60

Table 1.

Clinical parameters of experimental groups

Phenotype/genotype No. KW (g) BW (g) KW/BW (%) BUN (mg/dL)
(A) Cystic/TGF-α present 22 2.23 ± 0.64 8.92 ± 1.18 24.8 ± 5.1 93 ± 30
 bpk−/− TGF +/− 18 2.22 ± 0.67 8.90 ± 1.26 24.8 ± 5.1 89 ± 19
 bpk−/− TGF +/+ 4 2.26 ± 0.54 9.13 ± 0.87 24.8 ± 6.0 108 ± 52
(B) Noncystic/TGF-α present 48 0.14 ± 0.02 8.84 ± 0.88 1.60 ± 0.13 22 ± 4
 bpk+/− TGF +/− 25 0.14 ± 0.02 8.71 ± 0.74 1.57 ± 0.13 23 ± 5
 bpk+/− TGF +/+ 11 0.15 ± 0.02 9.29 ± 1.00 1.62 ± 0.14 22 ± 4
 bpk+/+ TGF +/− 8 0.14 ± 0.02 8.74 ± 1.08 1.61 ± 0.11 20 ± 4
 bpk+/+ TGF +/+ 4 0.14 ± 0.02 8.62 ± 0.86 1.64 ± 0.17 22 ± 6
(C) Cystic/TGF-α null 11 2.18 ± 0.51 8.5 ± 1.0 25.6 ± 5.2 106 ± 21
 bpk−/− TGF −/−
(D) Noncystic/TGF-α null 15 0.11 ± 0.02* 6.87 ± 1.23** 1.65 ± 0.10 26 ± 3
 bpk+/− TGF −/− 11 0.11 ± 0.02* 6.89 ± 1.29** 1.66 ± 0.09 26 ± 3
 bpk+/+ TGF −/− 4 0.11 ± 0.02* 6.81 ± 1.24** 1.62 ± 0.11 24 ± 3
*

p = 0.003, noncystic TGF absent vs present.

**

p = 0.001, noncystic TGF absent vs present.

HHS Vulnerability Disclosure